DIOSynVax is new technology that will significantly accelerate vaccine development and achieve dramatic improvements.
DIOSynVax has raised $42.0M in total funding. The most recent round was Grant. The last funding was announced in March 2022.
DIOSynVax's investors include Innovate UK, Parkwalk Advisors, Coalition for Epidemic Preparedness Innovations.
DIOSynVax is headquartered in Cambridge, United Kingdom.
DIOSynVax is new technology that will significantly accelerate vaccine development and achieve dramatic improvements.
DIOSynVax is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DIOSynVax — Funding & Investors." VCBacked, March 8, 2022, https://www.vcbacked.co/company/diosynvax. Accessed July 20, 2026.
VCBacked. (2022). DIOSynVax — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/diosynvax
{{cite web |title=DIOSynVax — Funding & Investors |url=https://www.vcbacked.co/company/diosynvax |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated